No Data
Shenzhen Neptunus Bioengineering (000078.SZ): NEP018 has received the drug clinical trial approval notification.
On March 10, Gelonghui reported that Shenzhen Neptunus Bioengineering (000078.SZ) announced that its wholly-owned subsidiary, Shenzhen Neptunus Pharmaceutical Technology Research Institute Co., Ltd. (referred to as "Neptunus Pharmaceutical Research Institute"), recently received the clinical trial approval notice for NEP018 tablets issued by the National Medical Products Administration. NEP018 tablets are a new type of small molecule kinase inhibitor targeting tumors, independently developed by the Neptunus Pharmaceutical Research Institute, with independent intellectual property rights. Comprehensive preclinical research has shown that NEP018 tablets have good selective inhibitory activity against the designed targets and demonstrate good inhibitory effects on gastrointestinal tumors.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Even After Rising 7.2% This Past Week, Shenzhen Neptunus Bioengineering (SZSE:000078) Shareholders Are Still Down 52% Over the Past Five Years
Neptune Biotech: 2024 Annual Results Forecast
Shenzhen Neptunus Bioengineering (000078.SZ): The company's current medical device business is approximately 10 billion yuan in size.
Gelonghui November 13th | Shenzhen Neptunus Bioengineering (000078.SZ) stated in investor relations that the medical device distribution business has a higher gross profit level compared to the pharmaceutical distribution business, with relatively minor influence from policies. Therefore, the medical devices business is one of the company's key development sectors, with the current medical device business size reaching about tens of billions. In the future, the company will expand the scale of medical device distribution and agency business, aiming to transition from market agents to entities with the right to represent foreign brands, by introducing advanced technology and high-quality products from foreign brands to further enhance the company's level and competitiveness in the medical device business.
Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Further Weakness as Shenzhen Neptunus Bioengineering (SZSE:000078) Drops 5.4% This Week, Taking Five-year Losses to 46%
